|Home | About | Journals | Submit | Contact Us | Français|
As a biomarker of smoking, semiquantitative analysis of cotinine (NicAlert®) offers several advantages over breath carbon monoxide (CO) and quantitative analysis of cotinine. Recent studies have used urine NicAlert® and breath CO in combination to verify abstinence. However, no studies have evaluated the performance of saliva NicAlert® against or in combination with breath CO.
Breath CO, saliva NicAlert®, and smoking history were compared in an urban population of daily smokers (n = 24) and nonsmokers (n = 25).
Saliva NicAlert® predicted self-reported smoking with 100% sensitivity and 96% specificity. At a cutoff of > 5 ppm, breath CO had 100% sensitivity and 100% specificity in predicting self-reported smoking. Breath CO was positively correlated with saliva NicAlert® and negatively correlated with minutes since last cigarette.
Saliva NicAlert® had high sensitivity and specificity in identifying daily smokers. Compared to saliva NicAlert®, breath CO level was more indicative of recent smoking. Future treatment studies should evaluate the performance of saliva NicAlert® as an alternative to the urine test.
Breath carbon monoxide (CO) is the most rapid, noninvasive, and easily measured biochemical indicator of smoking. However, several factors can affect its sensitivity and specificity (Benowitz, 2002). Breath CO measurement is only sensitive to recent smoking because CO has a short half-life (2–3 hours). Thus, breath CO readings following short and long term abstinence can be indistinguishable (Acosta et al., 2004; Gariti et al., 2002). The specificity of CO as a biomarker of smoking is limited by environmental sources of CO from pollution, motor vehicle exhaust, and passive smoke exposure (Jarvis and Russell, 1984). Thus, breath CO levels of nonsmokers exposed to environmental sources of CO (e.g. urban areas) can fall within the range of intermittent smokers (Cunnington and Hormbrey, 2002).
An ideal biomarker for smoking is cotinine, the major metabolite of nicotine, because it has a half-life of 10–30 hours (Benowitz, 2002). Quantitative analysis of cotinine is the “gold standard” for verifying smoking status, but it can be costly and time consuming. The recent development of NicAlert® colorimetric immunoassay tests allows for relatively inexpensive, easily measured, and rapid semiquantitative analysis of cotinine in saliva and urine. The major limitation of cotinine is that, due to its long half-life, it cannot discriminate between short term abstinence (< 24 hr) and continued smoking.
Because breath CO and cotinine differ in their ability to identify short and long term smoking abstinence, studies with inclusion criteria that require specific periods of abstinence, such as overnight tobacco deprivation or long term smoking abstinence, may require different biomarkers or biomarker combinations. For example, recent treatment studies have used NicAlert® tests in combination with breath CO to verify abstinence (Acosta et al., 2004; Schepis et al., 2008). In smokers attempting abstinence, CO [cutoff < 8 parts per million (ppm)] had a sensitivity of 83.1% and a specificity of 100%, whereas urine NicAlert® had a sensitivity of 98.5% and a specificity of 58.5% compared to cotinine assayed by gas chromatography/mass spectrometry (GC/MS) (Acosta et al., 2004). These data suggest that CO and urine NicAlert® may be more effective together than either measure alone in verifying self-reported abstinence (Acosta et al., 2004).
To our knowledge, no study has compared the relative sensitivities and specificities of breath CO and saliva NicAlert®. We compared saliva NicAlert® and breath CO to self-reported smoking status in daily smokers and nonsmokers to determine the feasibility of using saliva NicAlert® as an alternative to urine NicAlert®. We were interested in the performance of the NicAlert® saliva test because, relative to urine, saliva samples are easy to collect and may be considered less invasive.
Smokers (n = 24) and nonsmokers (n = 25) were recruited from the Baltimore metropolitan area via newspaper and radio advertisements. Participants were over the age of 18, had no chronic pulmonary disease, and reported no use of marijuana within 24 hr. Smokers were included if they reported smoking at least 5 cigarettes per day for the past 6 months and were not seeking treatment. Nonsmokers were included if they had not used any tobacco or nicotine products within the past 6 months. Of the smokers, 11 were Black (8 male, 3 female) and 13 were White (8 male, 5 female). Of the nonsmokers, 12 were Black (5 male, 7 female), 12 were White (4 male, 8 female), and one was Asian (male). One smoker was excluded because of poor forced vital capacity. Participants gave written informed consent according to guidelines for the protection of research volunteers of the U.S. Department of Health and Human Services and were paid for their participation. The NIDA Institutional Review Board approved the study.
Participants completed a single 20-min experimental session. After giving written informed consent, participants completed a brief smoking history questionnaire. Participants then gave a breath CO sample (Vitalograph, Lenexa, KS). Vitalograph readings range from 0 to 199 ppm with accuracy of ± 3 ppm. Finally, participants provided a saliva sample via passive drool that was tested with a NicAlert® dipstick (Nymox Corp., Hasbrouck Heights, NJ). The NicAlert® test yields a semiquantitative measure of cotinine based on a colorimetric immunoassay reaction. The test strip displays seven zones that represent a range of cotinine levels from 0 (0–10 ng/ml) to 6 (> 1000 ng/ml). Results were recorded as values from 0 to 6; a result ≥1 indicated tobacco use (see Table 1).
We used Receiver Operating Characteristic (ROC) analyses (Metz, 1978; Zweig and Campbell, 1993) to evaluate predictive accuracy between self-reported smoking and breath CO and between self-reported smoking and saliva NicAlert®. The CO cutoff level that optimally discriminated between smokers and nonsmokers was the value corresponding to the maximum of the Youden index (Youden, 1950): J = max[SEi + SPi − 1], where SEi and SPi are the sensitivity and specificity, respectively, over all possible cutoff values. ROC analyses were performed using MedCalc for Windows, version 220.127.116.11. We used t-tests to compare demographic and smoking history variables between smokers and nonsmokers, Whites and Blacks, and males and females. Pearson product-moment correlations were calculated between breath CO, saliva NicAlert®, and items on the smoking history questionnaire. All statistical tests were two-tailed, and results were considered significant at p < .05.
Mean age of smokers was 36.2 ± 8.5 yr (mean ± SD). They currently smoked 19.2 ± 9.0 cigarettes per day, had smoked daily for 14.2 ± 9.2 yr, had made 4.0 ± 5.4 lifetime quit attempts, and smoked their last cigarette 106.9 ± 105.8 min before the test session. Mean age of nonsmokers was 34.1 ± 9.7 yr. Twelve percent (3/25) reported smoking daily in the past; years smoking ranged from 1 to 15, and years since last cigarette ranged from 3 to 10. The remaining 22 nonsmokers reported smoking < 20 cigarettes in their life.
In smokers, mean breath CO was 21.4 ± 12.0 ppm (range 6–45); in nonsmokers, mean breath CO was 1.8 ± 1.0 ppm (range 1–5). Table 1 shows the distribution of NicAlert® readings in smokers and nonsmokers. As expected, breath CO and cotinine levels were significantly higher in smokers compared with nonsmokers (p’s < 0.001).
There were several differences between White and Black smokers. Compared with Blacks, Whites smoked more cigarettes per day (21.9 ± 7.5 vs. 15.9 ± 9.9, p = 0.05), reported more quit attempts (5.9 ± 6.8 vs. 1.9 ± 2.0, p < 0.05), and smoked more recently before the test session (51.9 ± 60.6 vs. 171.8 ± 113.1 min, p < 0.01). Consistent with these reports, White smokers had higher breath CO (25.2 ± 12.8 vs. 17.0 ± 9.7 ppm, p < 0.05) and saliva NicAlert® levels (5.3 ± 1.0 vs. 4.4 ± 1.2, p < 0.05). There were no differences between males and females with respect to demographic and smoking history variables.
Table 2A shows the results of ROC analysis using breath CO to predict self-reported smoking (prevalence = 49%). The cutoff indicating the optimal equilibrium between sensitivity and specificity was > 5 ppm. Table 2B shows the results of ROC analysis using saliva NicAlert® to predict self-reported smoking. The cutoff indicating the optimal equilibrium between sensitivity and specificity was > 0, which is the manufacturer’s recommended cutoff value.
Among all participants, there was a significant positive correlation between breath CO and saliva NicAlert® (r = 0.81, p < 0.001). For smokers, there was a significant negative correlation between breath CO and time since last cigarette (r = −0.56, p < 0.01). However, breath CO and number of cigarettes per day were not significantly correlated (r = 0.20, p > 0.1). Correlations between saliva NicAlert® and cigarettes per day (r = 0.34, p = .10) and time since last cigarette (r = −0.30) were not significant.
This was the first study to compare the sensitivities and specificities of saliva NicAlert® and breath CO to determine the feasibility of using saliva NicAlert® as an alternative to urine NicAlert®. Saliva NicAlert® and CO performed well in predicting self-reported smoking status. Breath CO and saliva NicAlert® had the same sensitivity, whereas CO had better specificity.
ROC analyses indicated that breath CO > 5 ppm predicted self-reported smoking with 100% sensitivity and specificity. The SRNT Subcommittee on Biochemical Verification recommended a cutoff of 8 ppm (Benowitz, 2002), which has been used by previous studies comparing CO and urine NicAlert® (Acosta et al., 2004; Schepis et al., 2008). If we had used this cutoff, sensitivity would have been 91.7% (Table 2A).
Saliva NicAlert® predicted self-reported smoking with 100% sensitivity and 96% specificity. In previous studies, its sensitivity and specificity were similar when compared against self-report (100% and 100%, respectively) (Cooke et al., 2008) and quantitative analysis of cotinine in urine (99% and 96%, respectively) (Montalto and Wells, 2007) and saliva (95% and 93%, respectively) (Cooke et al., 2008).
Breath CO was negatively correlated with minutes since last cigarette, whereas saliva NicAlert® was not. This is consistent with findings that breath CO levels are more indicative of recent smoking than cotinine (Schepis et al., 2008). In addition, compared with Black smokers, Whites smoked more cigarettes per day, had higher breath CO and saliva NicAlert® levels, and made more quit attempts. These findings are consistent with previous findings that racial differences in smoking behaviors and nicotine metabolism might contribute to variability in biomarkers of smoking (Andreski and Breslau, 1993; Cropsey et al., 2006; Luo et al., 2008; Perez-Stable et al., 1998).
This study was limited by its small sample size; however, our results were consistent with previous studies. Because we wanted an equal number of smokers and nonsmokers to test the feasibility of using saliva NicAlert®, smoking prevalence was constrained to 49%, which is much higher than the current smoking prevalence of 20% among adults in the United States (CDC, 2008). We tested daily smokers not interested in treatment, whereas previous studies comparing breath CO to cotinine examined treatment seekers (Acosta et al., 2004; Jatlow et al., 2008; Schepis et al., 2008). Breath CO and cotinine levels in individuals who recently began abstinence, relapsed, or were denying use during treatment might be different than in smokers not seeking treatment; such differences could impact the relative sensitivity and specificity of the biochemical methods. In addition, mean NicAlert® in smokers was 4.9, which seemed high (zone 4=200–500 ng/ml; zone 5=500–1000 ng/ml) compared with mean saliva cotinine levels previously measured by gas chromatography (e.g., 295 ng/ml; Jarvis et al., 2003). The NicAlert® manufacturer has reported that 3-hydroxycotinine showed 12–40% cross reactivity with cotinine in the NicAlert® assay in urine. Cross reactivity might explain the elevated NicAlert® levels observed among smokers in our study. In conclusion, our finding that saliva NicAlert® was highly sensitive and specific suggests that future treatment studies should evaluate the performance of saliva NicAlert® as an alternative to urine NicAlert®.
This research was supported by the Intramural Research Program of the NIH, National Institute on Drug Abuse. The authors have no conflicts of interest.